Skip to main content
Clinical Trials/NL-OMON32335
NL-OMON32335
Completed
Phase 3

Prevention of progression of duodenal adenomas to cancer in patients with familial adenomatous polyposis. - Duodenal adenomas and cancer in patients with FAP.

niversitair Medisch Centrum Sint Radboud0 sites120 target enrollmentStarted: TBDLast updated:

Overview

Phase
Phase 3
Status
Completed
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
120

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • \-Patients with FAP with duodenal adenomas of Spigelman stage II and III, with an indication for duodenoscopy
  • \-Patients with dyspeptic complaints with an indication for duodenoscopy, but without intestinal abnormalities.
  • \- Age between18\-70 years

Exclusion Criteria

  • \- Patients with a history of a cardiovascular accident, gallstones, gastric or duodenal ulcers, a prior allergic reaction on NSAIDs or UDCA or disturbed renal (creatinine clearance \< 50 ml/min.) or liver function (albumin \< 25 g/l or Child\-Pugh\-score \>\= 10\) will be excluded. No NSAIDs or UDCA may have been used during enrolment.
  • \- Cardiac patients NYHA class II\-IV.
  • \- Age below 18 or above 70 years or incapable to sign informed consent

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Similar Trials